The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder: - An experimental medicine blinded controlled trial

Danish Medical Journal

Volumn 59, Issue 4, 2012, Pages

  Knorr, Ulla Benedichte ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; ESCITALOPRAM; GLUCOCORTICOID; HYDROCORTISONE; PLACEBO; CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; BLOOD SAMPLING; COGNITION; DIARRHEA; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; DSM-IV; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EYSENCK PERSONALITY QUESTIONNAIRE; FOLLOW UP; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; INSOMNIA; LIBIDO DISORDER; MAJOR DEPRESSION; NAUSEA; NEUROPSYCHOLOGICAL TEST; NEUROSIS; ORGASM DISORDER; OUTCOME ASSESSMENT; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SEMI STRUCTURED INTERVIEW; SIDE EFFECT; SWEATING; TREMOR; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DRUG EFFECT; FEMALE; GENETICS; MALE; MIDDLE AGED; PEDIGREE; PERSONALITY TEST; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; STATISTICS;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CITALOPRAM; COGNITION; DENMARK; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEDIGREE; PERSONALITY TESTS; PSYCHOMETRICS; SELF REPORT; SEROTONIN UPTAKE INHIBITORS; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 84873128554     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (117)

1. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. A popula-tion-based twin study of major depression in women. The impact of varying definitions of illness. Arch Gen Psychiatry 1992;49:257-266.
2. Kessler RC, McGonagle KA, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
3. Olsen LR, Mortensen EL, Bech P. Prevalence of major depres-sion and stress indicators in the Danish general population. Acta Psychiatr Scand 2004;109:96-103.
4. Sobocki P, Jonsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ 2006;9:87-98.
5. Kessing LV, Hansen MG, Andersen PK. Course of illness in de-pressive and bipolar disorders. Naturalistic study, 1994-1999. Br J Psychiatry 2004;185:372-377.
6. Kessing LV, Andersen PK, Mortensen PB, Bolwig TG. Recurrence in affective disorder. I. Case register study. Br J Psychiatry 1998;172:23-28.
7. Kessing LV. Recurrence in affective disorder. II. Effect of age and gender. Br J Psychiatry 1998;172:29-34.
8. Ustun TB, yuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:386-392.
9. Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a reexamination. Am J Psychiatry 2000;157:1925-1932.
10. Hindmarch I. Beyond the monoamine hypothesis: mecha-nisms, molecules and methods. Eur Psychiatry 2002;17 Suppl 3:294-299.
11. Owens MJ. Selectivity of antidepressants: from the monoam-ine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry 2004;65 Suppl 4:5-10.
12. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-260.
13. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multi-ple-treatments meta-analysis. Lancet 2009.
14. Fournier JC, DeRubeis RJ, Hollon SD et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010;303:47-53.
15. Kemp AH, Gordon E, Rush AJ, Williams LM. Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr 2008;13:1066-1086.
16. Klysner R, Bent-Hansen J, Hansen HL et al. Efficacy of citalo-pram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry 2002;181:29-35.
17. Geddes JR, Carney SM, Davies C et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a system-atic review. Lancet 2003;361:653-661.
18. Dawson GR, Goodwin G. Experimental medicine in psychiatry. J Psychopharmacol 2005;19:565-566.
19. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000;157:1552-1562.
20. Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacol-ogy 2004;29:1765-1781.
21. Halligan SL, Herbert J, Goodyer IM, Murray L. Exposure to postnatal depression predicts elevated cortisol in adolescent offspring. Biol Psychiatry 2004;55:376-381.
22. Modell S, Lauer CJ, Schreiber W, Huber J, Krieg JC, Holsboer F. Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective dis-orders. Neuropsychopharmacology 1998;18:253-262.
23. Vinberg M, Bennike B, Kyvik KO, Andersen PK, Kessing LV. Salivary cortisol in unaffected twins discordant for affective disor-der. Psychiatry Res 2008;161:292-301.
24. Vinberg M, Mortensen EL, Kyvik KO, Kessing LV. Personality traits in unaffected twins discordant for affective disorder. Acta Psychiatr Scand 2007;115:442-450.
25. Kendler KS, Gatz M, Gardner CO, Pedersen NL. Personality and major depression: a Swedish longitudinal, population-based twin study. Arch Gen Psychiatry 2006;63:1113-1120.
26. Christensen MV, Kyvik KO, Kessing LV. Cognitive function in unaffected twins discordant for affective disorder. Psychol Med 2006;36:1119-1129.
27. Mannie ZN, Bristow GC, Harmer CJ, Cowen PJ. Impaired emo-tional categorisation in young people at increased familial risk of depression. Neuropsychologia 2007;45:2975-2980.
28. Mannie ZN, Barnes J, Bristow GC, Harmer CJ, Cowen PJ. Mem-ory impairment in young women at increased risk of depression: influence of cortisol and 5-HTT genotype. Psychol Med 2009;39:757-762.
29. Knorr U, Kessing LV. The effect of selective serotonin reuptake inhibitors in healthy subjects. A systematic review. Nord J Psychiatry 2010.
30. Holsboer F. The corticosteroid receptor hypothesis of depres-sion. Neuropsychopharmacology 2000;23:477-501.
31. Ising M, Kunzel HE, Binder EB, Nickel T, Modell S, Holsboer F. The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1085-1093.
32. Fuller RW, Snoddy HD. Serotonin receptor subtypes involved in the elevation of serum corticosterone concentration in rats by direct-and indirect-acting serotonin agonists. Neuroendocrinol-ogy 1990;52:206-211.
33. Jensen JB, Jessop DS, Harbuz MS, Mork A, Sanchez C, Mikkel-sen JD. Acute and long-term treatments with the selective sero-tonin reuptake inhibitor citalopram modulate the HPA axis activ-ity at different levels in male rats. J Neuroendocrinol 1999;11:465-471.
34. Seifritz E, Baumann P, Muller MJ et al. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. Neu-ropsychopharmacology 1996;14:253-263.
35. Bhagwagar Z, Hafizi S, Cowen PJ. Acute citalopram administra-tion produces correlated increases in plasma and salivary cortisol. Psychopharmacology (Berl) 2002;163:118-120.
36. Pariante CM, Papadopoulos AS, Poon L et al. Four days of citalopram increase suppression of cortisol secretion by predniso-lone in healthy volunteers. Psychopharmacology (Berl) 2004;177:200-206.
37. Nadeem HS, Attenburrow MJ, Cowen PJ. Comparison of the effects of citalopram and escitalopram on 5-Ht-mediated neuro-endocrine responses. Neuropsychopharmacology 2004;29:1699-1703.
38. Lotrich FE, Bies R, Muldoon MF, Manuck SB, Smith GS, Pollock BG. Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences. Psy-chopharmacology (Berl) 2005;178:268-275.
39. Jongsma ME, Bosker FJ, Cremers TI, Westerink BH, Den Boer JA. The effect of chronic selective serotonin reuptake inhibitor treatment on serotonin 1B receptor sensitivity and HPA axis activity. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:738-744.
40. Kendler KS, Myers J. The genetic and environmental relation-ship between major depression and the five-factor model of personality. Psychol Med 2009;1-6.
41. Huezo-Diaz P, Tandon K, Aitchison KJ. The genetics of depres-sion and related traits. Curr Psychiatry Rep 2005;7:117-124.
42. Tang TZ, DeRubeis RJ, Hollon SD, Amsterdam J, Shelton R, Schalet B. Personality change during depression treatment: a placebo-controlled trial. Arch Gen Psychiatry 2009;66:1322-1330.
43. Quilty LC, Meusel LA, Bagby RM. Neuroticism as a mediator of treatment response to SSRIs in major depressive disorder. J Affect Disord 2008;111:67-73.
44. Takano A, Arakawa R, Hayashi M, Takahashi H, Ito H, Suhara T. Relationship between neuroticism personality trait and serotonin transporter binding. Biol Psychiatry 2007;62:588-592.
45. Frokjaer VG, Vinberg M, Erritzoe D et al. High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. Neuroimage 2009.
46. Knutson B, Wolkowitz OM, Cole SW et al. Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry 1998;155:373-379.
47. Tse WS, Bond AJ. Serotonergic involvement in the psychoso-cial dimension of personality. J Psychopharmacol 2001;15:195-198.
48. Bech P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand Suppl 1986;326:1-37.
49. Arce E, Simmons AN, Lovero KL, Stein MB, Paulus MP. Escita-lopram effects on insula and amygdala BOLD activation during emotional processing. Psychopharmacology (Berl) 2007.
50. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 2006;59:816-820.
51. Tse WS, Bond AJ. Serotonergic intervention affects both social dominance and affiliative behaviour. Psychopharmacology (Berl) 2002;161:324-330.
52. Nemoto H, Toda H, Nakajima T et al. Fluvoxamine modulates pain sensation and affective processing of pain in human brain. Neuroreport 2003;14:791-797.
53. Rothen S, Vandeleur CL, Lustenberger Y et al. Personality traits in children of parents with unipolar and bipolar mood disor-ders. J Affect Disord 2009;113:133-141.
54. Christensen MV, Kessing LV. Do personality traits predict first onset in depressive and bipolar disorder? Nord J Psychiatry 2006;60:79-88.
55. Ravnkilde B, Videbech P, Clemmensen K, Egander A, Rasmussen NA, Rosenberg R. Cognitive deficits in major depression. Scand J Psychol 2002;43:239-251.
56. possible implications for functional neuropathology. Br J Psychiatry 2001;178:200-206.
57. Kessing LV. Cognitive impairment in the euthymic phase of affective disorder. Psychol Med 1998;28:1027-1038.
58. Sierksma AS, van den Hove DL, Steinbusch HW, Prickaerts J. Major depression, cognitive dysfunction and Alzheimer's disease: Is there a link? Eur J Pharmacol 2009.
59. Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry 2009;195:102-108.
60. Harmer CJ, O'Sullivan U, Favaron E et al. Effect of acute anti-depressant administration on negative affective bias in depressed patients. Am J Psychiatry 2009;166:1178-1184.
61. Miskowiak K, Papadatou-Pastou M, Cowen PJ, Goodwin GM, Norbury R, Harmer CJ. Single dose antidepressant administration modulates the neural processing of self-referent personality trait words. Neuroimage 2007;37:904-911.
62. Knorr U, Vinberg M, Klose M et al. Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepres-sive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression. Trials 2009;10:66.
63. ICH Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95), www.emea.int/pdfs/human/ich/013595en/pdf. 10-5-2006. 10-5-2006. Ref Type: Internet Communication
64. Wing JK, Babor T, Brugha T et al. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 1990;47:589-593.
65. Gotzsche PC. Blinding during data analysis and writing of manuscripts. Control Clin Trials 1996;17:285-290.
66. Mossner R, Mikova O, Koutsilieri E et al. Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry 2007;8:141-174.
67. Skovdahl-Hansen H, Mortensen EL Scioetz HK. Dokumentation for den danske udgave af NEO-PI-R og NEO-PI-R Kort Version. 2004. Copenhagen, Denmark, Dansk Psykologisk Forlag. Ref Type: Report
68. Eysenck HJ, Eysenck SGB. The Manual of the Eysenck Person-ality Questionnaire. London: Hodder and Stoughton, 1975.
69. Costa PT, Jr., McCrae RR. Stability and change in personality assessment: the revised NEO Personality Inventory in the year 2000. J Pers Assess 1997;68:86-94.
70. Nelson HE, O'Connell A. Dementia: the estimation of premor-bid intelligence levels using the New Adult Reading Test. Cortex 1978;14:234-244.
71. Waldemar G, Bruhn P, Kristensen M, Johnsen A, Paulson OB, Lassen NA. Heterogeneity of neocortical cerebral blood flow deficits in dementia of the Alzheimer type: a [99mTc]-d, l-HMPAO SPECT study. J Neurol Neurosurg Psychiatry 1994;57:285-295.
72. Reitan RM. Trail Making Test. Manual for Administration and Scoring. 1992. 2920 South 4th Avenue, South Tucson, Arizona 85713-4819, Reitan Neuropsychology Laboratory. Ref Type: Serial (Book, Monograph)
73. Golden CJ FS. Stroop Color an Word Test, revised 2002 adult Manual for Clincal and Experimental Uses. Stoelting, 2002.
74. Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. 2 nd edition. Philadelphia: 1983.
75. Gade A, Mortensen EL, Bruhn P. "Chronic painter's syn-drome". A reanalysis of psychological test data in a group of diagnosed cases, based on comparisons with matched controls. Acta Neurol Scand 1988;77:293-306.
76. Roth M, Tym E, Mountjoy CQ et al. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986;149:698-709.
77. Hawkins KA, Dean D, Pearlson GD. Alternative forms of the Rey Auditory Verbal Learning Test: a review. Behav Neurol 2004;15:99-107.
78. Akshoofmoff N, Stiles J. Developmental trends in visuospatial analysis and planning: Copying a complex figure. Neuropsychology 1995;9:364-377.
79. Yaretsky A, Arzi T, Ben-Nun Y. Word fluency in aging and dementia: principles of relatedness in the generative naming process. Arch Gerontol Geriatr 1999;29:57-60.
80. Sheridan LK, Fitzgerald HE, Adams KM et al. Normative Sym-bol Digit Modalities Test performance in a community-based sample. Arch Clin Neuropsychol 2006;21:23-28.
81. Haut MW, Kuwabara H, Leach S, Arias RG. Neural activation during performance of number-letter sequencing. Appl Neuropsy-chol 2000;7:237-242.
82. The Structured Clinical Interview for DSM-IV Axis II Personal-ity Disorders (SCID-II). Washington DC: American Psychiatric Press, 1997.
83. Lindstrom E, Lewander T, Malm U, Malt UF, Lublin H, Ahlfors UG. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry 2001;55 Suppl 44:5-69.
84. Vickers AJ, Altman DG. Statistics notes: Analysing controlled trials with baseline and follow up measurements. BMJ 2001;323:1123-1124.
85. ICH Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95), www.emea.int/pdfs/human/ich/013595en/pdf. 10-5-2006. 10-5-2006. Ref Type: Internet Communication
86. Schule C, Baghai TC, Eser D et al. The combined dexa-methasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression. PLoS One 2009;4:e4324.
87. Du L, Bakish D, Ravindran AV, Hrdina PD. Does fluoxetine influence major depression by modifying five-factor personality traits? J Affect Disord 2002;71:235-241.
88. Fairweather D, Pozzo C, Kerr J, Lafferty S, Hindmarch I. Citalo-pram Compared to Dothiepin and Placebo: effects on Cognitive Function and Psychomotor Performance. Human Psychopharma-cology 1997;12:119-126.
89. Schmitt JA, Kruizinga MJ, Riedel WJ. Non-serotonergic phar-macological profiles and associated cognitive effects of serotonin reuptake inhibitors. J Psychopharmacol 2001;15:173-179.
90. Loubinoux I, Tombari D, Pariente J et al. Modulation of behav-ior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer. Neuroimage 2005;27:299-313.
91. Robbe HW, O'Hanlon JF. Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor per-formance and subjective assessments in healthy volunteers. Eur Neuropsychopharmacol 1995;5:35-42.
92. Riedel WJ, Eikmans K, Heldens A, Schmitt JA. Specific seroton-ergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment. J Psychopharmacol 2005;19:12-20.
93. Ramaekers JG, Muntjewerff ND, O'Hanlon JF. A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. Br J Clin Pharmacol 1995;39:397-404.
94. Schmitt JA, Ramaekers JG, Kruizinga MJ, van Boxtel MP, Vuurman EF, Riedel WJ. Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. J Psychopharmacol 2002;16:207-214.
95. Wingen M, Langer S, Ramaekers JG. Verbal memory perform-ance during subchronic challenge with a selective serotonergic and a mixed action antidepressant. Hum Psychopharmacol 2006;21:473-479.
96. Paul MA, Gray G, Lange M. The impact of sertraline on psy-chomotor performance. Aviat Space Environ Med 2002;73:964-970.
97. Paul MA, Gray GW, Love RJ, Lange M. SSRI effects on pyscho-motor performance: assessment of citalopram and escitalopram on normal subjects. Aviat Space Environ Med 2007;78:693-697.
98. Wingen M, Bothmer J, Langer S, Ramaekers JG. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 2005;66:436-443.
99. Allen D, Lader M, Curran HV. A comparative study of the interactions of alcohol with amitriptyline, fluoxetine and placebo in normal subjects. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:63-80.
100. Wilson SJ, Bailey JE, Alford C, Weinstein A, Nutt DJ. Effects of 5 weeks of administration of fluoxetine and dothiepin in normal volunteers on sleep, daytime sedation, psychomotor performance and mood. J Psychopharmacol 2002;16:321-331.
101. Peran P, Demonet JF, Cardebat D. Paroxetine-induced modu-lation of cortical activity supporting language representations of action. Psychopharmacology (Berl) 2008;195:487-496.
102. Schmitt JA, Riedel WJ, Vuurman EF, Kruizinga M, Ramaekers JG. Modulation of the critical flicker fusion effects of serotonin reuptake inhibitors by concomitant pupillary changes. Psy-chopharmacology (Berl) 2002;160:381-386.
103. Siepmann M, Grossmann J, Muck-Weymann M, Kirch W. Effects of sertraline on autonomic and cognitive functions in healthy volunteers. Psychopharmacology (Berl) 2003;168:293-298.
104. Drueke B, Baetz J, Boecker M et al. Differential effects of escitalopram on attention: a placebo-controlled, double-blind cross-over study. Psychopharmacology (Berl) 2009.
105. Heuser I, Yassouridis A, Holsboer F. The combined dexa-methasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 1994;28:341-356.
106. Kunugi H, Ida I, Owashi T et al. Assessment of the dexa-methasone/CRH test as a state-dependent marker for hypotha-lamic-pituitary-adrenal (HPA) axis abnormalities in major depres-sive episode: a Multicenter Study. Neuropsychopharmacology 2006;31:212-220.
107. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalo-pram and R-fluoxetine. Biol Psychiatry 2001;50:345-350.
108. Klose M, Lange M, Rasmussen AK et al. Factors influencing the adrenocorticotropin test: role of contemporary cortisol as-says, body composition, and oral contraceptive agents. J Clin Endocrinol Metab 2007;92:1326-1333.
109. Bech P, Andersen HF, Wade A. Effective dose of escitalopram in moderate versus severe DSM-IV major depression. Pharma-copsychiatry 2006;39:128-134.
110. Gluud C. The culture of designing hepato-biliary randomised trials. J Hepatol 2006;44:607-615.
111. Gluud LL. Bias in clinical intervention research. Am J Epide-miol 2006;163:493-501.
112. Guyatt GH, Mills EJ, Elbourne D. In the era of systematic reviews, does the size of an individual trial still matter. PLoS Med 2008;5:e4.
113. Christensen E. Methodology of superiority vs. equivalence trials and non-inferiority trials. J Hepatol 2007;46:947-954.
114. Sogaard B, Mengel H, Rao N, Larsen F. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol 2005;45:1400-1406.
115. Nikisch G, Mathe AA, Czernik A et al. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentra-tions in plasma and cerebrospinal fluid (CSF) and clinical re-sponse. Psychopharmacology (Berl) 2005;181:751-760.
116. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636-645.
117. Leuchter AF, Cook IA, Hunter AM, Korb AS. A new paradigm for the prediction of antidepressant treatment response. Dialo-gues Clin Neurosci 2009;11:435-446.